Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically comparing Dr. Pen and Derminator for hair growth. The user is seeking advice on affordable options due to a low income.

The conversation discusses using azelaic acid to reduce scalp inflammation while using RU58841 for hair loss. It suggests applying azelaic acid in the morning and RU58841 at night to avoid degradation, while also using dutasteride and minoxidil.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

Finasteride has been effective for maintaining hair density, but due to a slight dip in temple hair, the user switched to dutasteride as an additional measure. Users discuss varying experiences with side effects from finasteride, dutasteride, and minoxidil, highlighting that reactions can differ significantly among individuals.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.

The conversation is about using a Dr. Pen for microneedling on a widow's peak, with advice to use a depth of 1.25mm and hold it in place for 10 seconds. The user is also using minoxidil.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

Iron and zinc vitamins helped improve hairline regrowth for someone with celiac disease. Nutrient deficiencies, like iron, can contribute to hair loss, especially around the temples.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

A user is using topical dutasteride, topical finasteride, and minoxidil to address a receding hairline and is seeking opinions on their routine. They report seeing vellus hair growth after nearly three months of use.

Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The user experienced worsening hair density despite using finasteride, minoxidil, dutasteride, and RU58841, with some temporary improvement after stopping RU58841. Currently, they are on 2.5mg dutasteride daily and topical minoxidil, but continue to struggle with hair density issues.

Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

The conversation is about evaluating the ingredients in Davines VOLU shampoo for potential red flags. The user is concerned about which ingredients to avoid despite the shampoo being sulfate-free.

Apply minoxidil at least 1-2 hours before bed to ensure it dries and doesn't transfer to the pillow. Foam dries faster than liquid, and using a satin beanie after drying can help prevent transfer.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

The conversation discusses hair regrowth after a health condition, with the appearance of white substance on the scalp. Suggestions include it being sebum or White Piedra, with a recommendation to try Nizoral.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The user experienced red pimples and a rash from using topical minoxidil, possibly due to propylene glycol. Suggestions included seeing a dermatologist, switching to foam without propylene glycol, using Nizoral, and adjusting application timing.

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

Hair regrowth after addressing iron/zinc deficiency. Treatments mentioned include daily supplements of iron and zinc.